Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm

Franco Locatelli, MD, Kathleen A Neville, MD, MS, Angelo Rosolen, MD, Judith Landman-Parker, MD, Nathalie Aladjidi, MD, Auke Beishuizen, MD, Stephen Daw, BSc Hons, MBChB, MRCP, Lia Gore, MD, Anna R.K. Franklin, MD, Adedigbo Fasanmade, PhD, Jingyuan Wang, PhD, Jessica Sachs, MD, Christine Mauz-Koerholz, MD

Blood (2013) 122 (21): 4378.

https://doi.org/10.1182/blood.V122.21.4378.4378

Published: 2013

Journal Articles

Early Assessment of Minimal Residual Disease (MRD) by Qualitative PCR for NPM-ALK Identifies Patients At Very High Risk of Relapse in Anaplastic Large Cell Lymphoma

Christine Damm-Welk, PhD, Lara Mussolin, PhD, Marta Pillon, MD, Martin Zimmermann, PhD, Alfred Reiter, MD, Wilhelm Woessmann, MD, Angelo Rosolen, MD

Blood (2011) 118 (21): 1565.

https://doi.org/10.1182/blood.V118.21.1565.1565

Published: 2011

Journal Articles

MiR-28 Silencing In Germinal Center-Derived Lymphomas

Christof Schneider, MD, Roy L Maute, Pavel Sumazin, PhD, Manisha Brahmachary, PhD, Manu Setty, Laura Pasqualucci, MD, Angelo Rosolen, MD, Christina Leslie, PhD, Katia Basso, PhD, Riccardo Dalla-Favera, MD

Blood (2010) 116 (21): 703.

https://doi.org/10.1182/blood.V116.21.703.703

Published: 2010

Journal Articles

Investigating Mature B-Cell Lymphomas by MicroRNA Profiling.

Katia Basso, PhD, Pavel Morozov, PhD, Yukiko Kitagawa, MD, Roy L. Maute, Angelo Rosolen, MD, Chang-Zheng Chen, PhD, Andrea Califano, PhD, Riccardo Dalla-Favera, MD

Blood (2007) 110 (11): 3185.

https://doi.org/10.1182/blood.V110.11.3185.3185

Published: 2007

Journal Articles

Anaplastic Large Cell Lymphoma (ALCL) in Children: Equal Efficacy but Greater Toxicity of Chemotherapy Including Methotrexate (MTX) 1g/m 2 in 24 Hour Infusion with Intra-Thecal Injection (IT) Than Chemotherapy with MTX 3g/m 2 in 3 Hours Infusion without IT: Results of the ALCL99-R1 Randomised Trial.

Laurence Brugières, MD, Marie Cécile Le Deley, MD, Angelo Rosolen, MD, Denise Williams, MD, Ke Horibe, MD, Grazyna Wrobel, MD, Anne Uyttebroeck, MD, Auke Beishuizen, MD, Georg Mann, MD, Karin Mellgren, MD, Alfred Reiter, MD

Blood (2006) 108 (11): 398.

https://doi.org/10.1182/blood.V108.11.398.398

Published: 2006

Journal Articles

Identification of Normal and Neoplastic Human Mature B Cells “miRome”.

Katia Basso, PhD, Pavel Morozov, PhD, Andrea Califano, PhD, Angelo Rosolen, MD, Jacqueline Chau, Chang-Zheng Chen, PhD, Riccardo Dalla-Favera, MD

Blood (2006) 108 (11): 2239.

https://doi.org/10.1182/blood.V108.11.2239.2239

Published: 2006

NARROW

Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm

Early Assessment of Minimal Residual Disease (MRD) by Qualitative PCR for NPM-ALK Identifies Patients At Very High Risk of Relapse in Anaplastic Large Cell Lymphoma

MiR-28 Silencing In Germinal Center-Derived Lymphomas

Investigating Mature B-Cell Lymphomas by MicroRNA Profiling.

Anaplastic Large Cell Lymphoma (ALCL) in Children: Equal Efficacy but Greater Toxicity of Chemotherapy Including Methotrexate (MTX) 1g/m 2 in 24 Hour Infusion with Intra-Thecal Injection (IT) Than Chemotherapy with MTX 3g/m 2 in 3 Hours Infusion without IT: Results of the ALCL99-R1 Randomised Trial.

Identification of Normal and Neoplastic Human Mature B Cells “miRome”.

Email alerts

ASH Publications

American Society of Hematology

Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm

Early Assessment of Minimal Residual Disease (MRD) by Qualitative PCR for NPM-ALK Identifies Patients At Very High Risk of Relapse in Anaplastic Large Cell Lymphoma

MiR-28 Silencing In Germinal Center-Derived Lymphomas

Investigating Mature B-Cell Lymphomas by MicroRNA Profiling.

Identification of Normal and Neoplastic Human Mature B Cells “miRome”.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only